AR015986A1 - Derivados de eritromicina puenteados en 6,11, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procedimientospara su preparacion - Google Patents
Derivados de eritromicina puenteados en 6,11, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procedimientospara su preparacionInfo
- Publication number
- AR015986A1 AR015986A1 ARP980105375A ARP980105375A AR015986A1 AR 015986 A1 AR015986 A1 AR 015986A1 AR P980105375 A ARP980105375 A AR P980105375A AR P980105375 A ARP980105375 A AR P980105375A AR 015986 A1 AR015986 A1 AR 015986A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroarylene
- arylene
- absent
- substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Derivados de eritromicina 6,11-puenteados y sales y ésteres de los mismos farmacéuticamante aceptables que tienen actividad antibacteriana y que tienen laformula (I) o (II), en la cuál: m es 0, 1, 2, 3, 4, 5, 6 o 7; n es 0, 1, 2, 3 o 4; Rp es independientemente hidrogeno o un grupo protector hidroxi cada vez queocurre; A está ausente o se selecciona entre -O-, y -N(R1)-, donde R1 es hidrogeno o alquilo C1-6 opcionalmente substituido con arilo o heteroarilo; B estáausente o está seleccionado delgrupo que consiste en: -(CH2)q-, donde q es 0, 1, 2, 3, 4, 5 o 6, -C(O)-(CH2)q-, -C(O)-O-(CH2)q-, -C(O)-NR1-(CH2)q, donde R1 estal como se ha definido previamente, -N=CH-(CH2)q-, y -CH(OH)-CH(OH)-(CH2)q-; D está ausente o es selecciona do del grupo que consiste en: alquileno, arileno,arileno sustituido, heteroarileno, heteroarileno sustituido, alquileno-arileno, arileno-arileno, arileno sustituido-arileno, heteroarileno-arileno,heteroarileno sustituido-arileno, alquenileno-heteroarileno, arileno-heteroarileno, arileno sustituido-heteroarileno, heteroarileno-heteroarileno, yheteroarileno sustituido-heteroarileno; E está ausente o está seleccionado del grupo que consiste en: -(CH2)r-CH=CH-, -(CH2)r-O-, donde r es 0, 1, 2, 3 o 4,-(CH2)r-NR1-CH2-CH(OH)-, donde R1 es tal como se ha definido previamente, -(CH2)r-C(O)-O-, -(CH2)r-N(R1)-, -(CH2)r-O-C(O)-, -(CH2)r-C(O)-N(R1)-, y-(CH2)r-N(R1)-C(O)-; con las restricciones de que la suma de m + q no puede ser 0, que la suma de m + n + q + r es unnumero de 2 a 7, que cuando las porcionesA y B están ambas ausentes entonces m no puede ser 0, que cuando E es -CH=CH- y las porciones A, B y D están todas ausentes entonces m no puede ser 0 y que Bpuede ser -N=CH-(CH2)q- unicamente cuando A está ausente y m es 0; composiciones farmacéuticas que comprenden una cantidad terapéuticamente eficaz de dichocompuesto en combinacion con un portador farmacéuticamente aceptable, su uso para la manufactura de un medicamento util para tratar infecciones bacterianasmediante la administracion a un mamífero de una composicion farmacéutica que contiene una cantidad terapéuticamente eficaz de dicho compuesto, y procedimientos
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96040097A | 1997-10-29 | 1997-10-29 | |
| US15826998A | 1998-09-22 | 1998-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015986A1 true AR015986A1 (es) | 2001-05-30 |
Family
ID=26854886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105375A AR015986A1 (es) | 1997-10-29 | 1998-10-27 | Derivados de eritromicina puenteados en 6,11, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procedimientospara su preparacion |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1027361B1 (es) |
| JP (1) | JP2001521038A (es) |
| KR (1) | KR20010031591A (es) |
| CN (1) | CN1278266A (es) |
| AR (1) | AR015986A1 (es) |
| AT (1) | ATE239750T1 (es) |
| AU (1) | AU1286799A (es) |
| BG (1) | BG104425A (es) |
| BR (1) | BR9813317A (es) |
| CA (1) | CA2307828A1 (es) |
| CO (1) | CO4990972A1 (es) |
| DE (1) | DE69814441T2 (es) |
| DK (1) | DK1027361T3 (es) |
| ES (1) | ES2198766T3 (es) |
| HU (1) | HUP0004323A2 (es) |
| IL (1) | IL134996A0 (es) |
| NO (1) | NO20002099L (es) |
| PL (1) | PL340253A1 (es) |
| PT (1) | PT1027361E (es) |
| SK (1) | SK6342000A3 (es) |
| TR (1) | TR200001140T2 (es) |
| TW (1) | TW486485B (es) |
| WO (1) | WO1999021864A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437106B1 (en) * | 1999-06-24 | 2002-08-20 | Abbott Laboratories | Process for preparing 6-o-substituted erythromycin derivatives |
| US6472372B1 (en) * | 2000-12-06 | 2002-10-29 | Ortho-Mcneil Pharmaceuticals, Inc. | 6-O-Carbamoyl ketolide antibacterials |
| US6713455B2 (en) | 2001-09-17 | 2004-03-30 | Ortho-Mcneil Pharmaceutical, Inc. | 6-O-carbamate-11,12-lacto-ketolide antimicrobials |
| CA2469304A1 (en) | 2001-12-05 | 2003-06-19 | Ortho-Mcneil Pharmaceutical, Inc. | 6-o acyl ketolide antibacterials |
| US6753318B1 (en) | 2002-07-25 | 2004-06-22 | Enanta Pharmaceuticals, Inc. | 6,11-4-carbon bridged erythromycin derivatives |
| US6841664B2 (en) * | 2002-07-25 | 2005-01-11 | Enanra Pharmaceuticals, Inc. | 6,11-4-carbon bridged ketolides |
| JP2005536465A (ja) | 2002-05-13 | 2005-12-02 | エナンタ ファーマシューティカルズ インコーポレイテッド | ６，１１二環式エリスロマイシン誘導体 |
| US7910558B2 (en) * | 2002-05-13 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Bridged macrocyclic compounds and processes for the preparation thereof |
| AU2003229037B8 (en) * | 2002-05-13 | 2009-07-02 | Enanta Pharmaceuticals, Inc. | 6,11 bicyclic erythromycin derivatives |
| US7273853B2 (en) | 2002-05-13 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | 6-11 bicyclic ketolide derivatives |
| US6645941B1 (en) * | 2003-03-26 | 2003-11-11 | Enanta Pharmaceuticals, Inc. | 6,11-3C-bicyclic 9a-azalide derivatives |
| US7414030B2 (en) | 2004-01-07 | 2008-08-19 | Enanta Pharmaceuticals, Inc. | 6-11 Bicyclic erythromycin derivatives |
| WO2005070113A2 (en) | 2004-01-09 | 2005-08-04 | Enanta Pharmaceuticals, Inc. | 9n-substituted 6-11 bicyclic erythromycin derivatives |
| WO2005080408A1 (en) * | 2004-01-23 | 2005-09-01 | Enanta Pharmaceuticals, Inc. | Bridged macrocyclic compounds and processes for the preparation thereof |
| US7384921B2 (en) | 2004-02-20 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | Polymorphic forms of 6-11 bicyclic ketolide derivatives |
| US7384922B2 (en) | 2005-05-04 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | 6-11 bridged oxime erythromycin derivatives |
| US7589067B2 (en) | 2005-10-12 | 2009-09-15 | Enanta Pharmaceuticals, Inc. | 6, 11-bridged tricyclic macrolides |
| US8273720B2 (en) | 2007-09-17 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | 6,11-bicyclolides: bridged biaryl macrolide derivatives |
| US11673910B2 (en) | 2017-04-28 | 2023-06-13 | Zikani Therapeutics, Inc. | Macrolides with modified desosamine sugars and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0876388T3 (da) * | 1995-11-08 | 2004-06-07 | Abbott Lab | Tricykliske erythromycinderivater |
-
1998
- 1998-10-27 AR ARP980105375A patent/AR015986A1/es unknown
- 1998-10-27 CO CO98062727A patent/CO4990972A1/es unknown
- 1998-10-29 WO PCT/US1998/022941 patent/WO1999021864A1/en not_active Application Discontinuation
- 1998-10-29 DK DK98956314T patent/DK1027361T3/da active
- 1998-10-29 BR BR9813317-9A patent/BR9813317A/pt not_active IP Right Cessation
- 1998-10-29 KR KR1020007004641A patent/KR20010031591A/ko not_active Application Discontinuation
- 1998-10-29 ES ES98956314T patent/ES2198766T3/es not_active Expired - Lifetime
- 1998-10-29 IL IL13499698A patent/IL134996A0/xx unknown
- 1998-10-29 PL PL98340253A patent/PL340253A1/xx unknown
- 1998-10-29 AT AT98956314T patent/ATE239750T1/de not_active IP Right Cessation
- 1998-10-29 HU HU0004323A patent/HUP0004323A2/hu unknown
- 1998-10-29 DE DE69814441T patent/DE69814441T2/de not_active Expired - Fee Related
- 1998-10-29 PT PT98956314T patent/PT1027361E/pt unknown
- 1998-10-29 CA CA002307828A patent/CA2307828A1/en not_active Abandoned
- 1998-10-29 EP EP98956314A patent/EP1027361B1/en not_active Expired - Lifetime
- 1998-10-29 AU AU12867/99A patent/AU1286799A/en not_active Abandoned
- 1998-10-29 JP JP2000517973A patent/JP2001521038A/ja not_active Withdrawn
- 1998-10-29 CN CN98810785A patent/CN1278266A/zh active Pending
- 1998-10-29 SK SK634-2000A patent/SK6342000A3/sk unknown
- 1998-10-29 TR TR2000/01140T patent/TR200001140T2/xx unknown
- 1998-11-30 TW TW087117981A patent/TW486485B/zh active
-
2000
- 2000-04-25 NO NO20002099A patent/NO20002099L/no not_active Application Discontinuation
- 2000-05-11 BG BG104425A patent/BG104425A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002099L (no) | 2000-06-29 |
| JP2001521038A (ja) | 2001-11-06 |
| PT1027361E (pt) | 2003-09-30 |
| TR200001140T2 (tr) | 2001-05-21 |
| EP1027361A1 (en) | 2000-08-16 |
| CA2307828A1 (en) | 1999-05-06 |
| IL134996A0 (en) | 2001-05-20 |
| EP1027361B1 (en) | 2003-05-07 |
| BG104425A (bg) | 2001-01-31 |
| DE69814441D1 (de) | 2003-06-12 |
| DK1027361T3 (da) | 2003-08-25 |
| SK6342000A3 (en) | 2000-09-12 |
| WO1999021864A1 (en) | 1999-05-06 |
| NO20002099D0 (no) | 2000-04-25 |
| ATE239750T1 (de) | 2003-05-15 |
| ES2198766T3 (es) | 2004-02-01 |
| AU1286799A (en) | 1999-05-17 |
| BR9813317A (pt) | 2000-08-22 |
| HUP0004323A2 (hu) | 2001-02-28 |
| TW486485B (en) | 2002-05-11 |
| PL340253A1 (en) | 2001-01-29 |
| KR20010031591A (ko) | 2001-04-16 |
| DE69814441T2 (de) | 2004-04-08 |
| CN1278266A (zh) | 2000-12-27 |
| CO4990972A1 (es) | 2000-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015986A1 (es) | Derivados de eritromicina puenteados en 6,11, composiciones farmaceuticas que los contienen, su uso para la manufactura de un medicamento y procedimientospara su preparacion | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| KR920702220A (ko) | 산화적 손상에 관련된 질병을 억제하기 위한 방법 및 그 조성물 | |
| AU728826B2 (en) | Compositions for treating and preventing arterial thrombosis and use of a factor Xa inhibitor on its own and/or combined with a platelet antiaggregating agent | |
| AR035482A1 (es) | Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos | |
| RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
| DK1140745T3 (da) | Colchinolderivater som vaskulært skadelige midler | |
| HRP20060275B1 (hr) | 6-0-supstituirani ketolidi antibakterijskog djelovanja | |
| SE9901573D0 (sv) | New compounds | |
| KR940701264A (ko) | 안과질환에 대한 마크로라이드 화합물의 용도 | |
| SK287972B6 (sk) | Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof | |
| MX2023001756A (es) | Peptidos funcionalizados como agentes antivirales. | |
| AR058619A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
| NO304113B1 (no) | Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament | |
| AR015434A1 (es) | Derivados de eritromicina con puente en 6,9, procedimientos para su preparacion, composicion farmaceutica para tratar infecciones bacterianas que los contiene y su uso para la manufactura de un medicamento | |
| NO20001439L (no) | 3'-N-modifiserte 6-O-substituerte erytromycin ketolid- derivater med antibakteriell aktivitet | |
| BR9911300A (pt) | Composto, composição farmacêutica, e, uso do composto | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| US3011945A (en) | Phenylcyclopropylamine -10-(omega-aminoalkyl)-phenothiazine ataractic composition | |
| RU94045866A (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения | |
| SE9901572D0 (sv) | New compounds | |
| UY26459A1 (es) | 3,4-dihidroquinazolinas 5,6-disustituidas | |
| KR960703593A (ko) | (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine) | |
| BR0013435A (pt) | Composto, um derivado de éster, de éter ou de n-alquila farmaceuticamente aceitável do mesmo ou um sal farmaceuticamente aceitável dos mesmos, medicamento, composição e método para a prevenção ou tratamento de uma infeção, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |